C3/C3c Antibody (Monoclonal)

A murine monoclonal antibody to an epitope in the C3c domain of C3.


Product Specifications

Citations16
Clonality

Monoclonal

Immnogen

Purified human protein.

Applications

See citations and technical data sheet for application info.

Concentration≥ 1.0 mg/mL
ConjugateUnconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog NumberA205
Catalog Number (CE)N/A
Size100 µl
Price (USD)$365.00
Price (EURO)330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to an epitope in the C3c domain of C3.

Size

100 µl

Concentration≥ 1.0 mg/mL
ApplicationsSee citations and technical data sheet for application info.
FormLiquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
ClonalityMonoclonal
Immunogen

Purified human protein.

ConjugateUnconjugated
Cross ReactivityHuman
Isotype

IgG1k

Purity

> 95% by SDS PAGE

SourceMouse
Specificity

This monoclonal antibody was raised against purified human C3. It is specific for an antigen expressed on the C3c domain of C3 and therefore reactive to C3 and all C3c-containing fragments of C3.

Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The human complement component C3 consists of two disulfide bonded subunits (Alpha 115,000 kD and Beta 75,000 kD). The concentration of C3 in serum is approximately 1.25 +/– 0.52 mg/ml. Under normal conditions, activation of either of the complement pathways leads to C3 convertases, which cleave C3 into two fragments C3a, an anaphylatoxin, and C3b. The C3b fragment has many biologic functions including promotion of phagocytosis and participation as a structural component of both the C3 and C5 convertase enzymes. These processes are under stringent control in vivo. One control mechanism involves a two-site cleavage of C3b by Factor I with the cooperation of Factor H or CR1 as cofactors. When cleaved in this way the biologic functions of C3b are lost. The resulting protein is termed iC3b. iC3b can remain covalently bound to a target cell or bind CR3 receptors. It can be further broken down to C3c and C3d,g. 1 Quidel’s monoclonal antibodies to complement antigens were prepared using standard techniques. They are purified from mouse ascites fluid via protein A affinity chromatography. Quidel’s Monoclonal anti human C3c was raised against highly pure, human C3 using standard techniques. The specificity of the monoclonal antibody was established via a series of immunoassays utilizing highly purified C3 and C3 fragments. Firstly, the antibody was shown by ELISA to bind to purified C3, iC3b and C3c immobilized in microtiter wells, but not other complement proteins nor C3 fragments. Secondly, free (unbound) C3, iC3b, C3c and human serum but not other C3 fragments were shown (via inhibition EIA) to inhibit the binding of this antibody to immobilized C3.

Citations

TitleYearApplicationsSample SpeciesSampleSample Details

Mechanism of Borrelia immune evasion by FhbA-related proteins

2022WBBacteria

Borrelia hermsii

N/A

Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration.

2021ELISAHuman

Eye Tissue

Age-Related Macular Degeneration

Complement-Mediated Selective Tumor Cell Lysis Enabled by Bi-Functional RNA Aptamers.

2021IFCell Culture

MDA-MB-231 Cells

N/A

Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.

2020FCCell Culture

HUVEC Cells

N/A

Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme.

2019FCCell Culture

HUVEC Cells

N/A

Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.

2018ELISAHuman

Plasma

Platelet factor 4 (PF4)/heparin complexes

Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1.

2018FCCell Culture

Endothelial Cells

HUVEC Cells, HMEC Cells, HRGEC Cells

Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

2018FCHuman

HUVEC Cells

Microvesicles with heme

Role of complement receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney

2015FCCell Culture

CHO Cells

N/A

Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome

2015FCCell Culture

HUVEC Cells

N/A

Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis

2015FCHuman

Endothelial Cells

N/A

Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?

2014FCCell Culture

HUVEC Cells

N/A

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

2013FCHuman

HUVEC Cells

aHUS

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

2012FCCell Culture

GEnCs cells

N/A

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

2012FCCell Culture

HUVEC Cells

N/A

Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells

2002FCHamster

CHO Cells

MCP Transfected